DHDehao Huang

Dehao Huang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Dehao Huang has a total of 49 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    iPSC ‐Derived iNK Progenitors Engraft and Generate NK Cells in Unconditioned and Autologous Immune Humanized Mice

    by Min Zhang, Zhiqian Wang, Yanhong Liu, Leqiang Zhang, Fangxiao Hu, Chengxiang Xia, Mengyun Zhang, Tongjie Wang, Qitong Weng, Hanmeng Qi, et al.

    NK cells exhibit inherently short persistence in vivo. Allo‐NK cells trigger host immune rejection in immune‐competent patients. Lymphodepletion is a conventional approach for mitigating allogeneic rejection of therapeutic NK cells, which brings host immune suppression and infection risks. To address these problems, we test the concept of engrafting iNK progenitor (iNKP) cells derived from human induced pluripotent stem cells (iPSC) to achieve generating iNK cells in vivo in unconditioned host‐immune humanised mice without the requirement for prior lymphodepleting chemotherapy or total body irradiation. Our results showed that a single low‐dose infusion of iNKP cells successfully engrafted and continuously produced mature iNK cells in unconditioned B‐NDG hIL15 mice. Furthermore, the iPSC‐derived iNKP cells survived in the presence of autologous PBMC‐humanised mice and generated mature iNK cells. This study provides evidence that autologous iPSC‐derived iNKP cells have the application potential for treating the same individual without the preceding necessity of lymphodepletion.

  • Open Access

    Publisher Correction: Large-scale generation of iNK and CAR-iNK cells from CD34+ haematopoietic stem and progenitor cells for adoptive immunotherapy

    by Fangxiao Hu, Jianhuan Li, Yao Wang, Yunqing Lin, Jingliao Zhang, Jiacheng Xu, Xiujuan Zheng, Qitong Weng, Xiaofei Liu, Yang Geng, et al.

  • Large-scale generation of iNK and CAR-iNK cells from CD34+ haematopoietic stem and progenitor cells for adoptive immunotherapy

    by Fangxiao Hu, Jianhuan Li, Yao Wang, Yunqing Lin, Jingliao Zhang, Jiacheng Xu, Xiujuan Zheng, Qitong Weng, Xiaofei Liu, Yang Geng, et al.

    Chimaeric antigen receptor (CAR) natural killer (CAR-NK) cells are a promising alternative to CAR-T cells for immunotherapies. High and multiple doses of CAR-NK cell infusions are essential to maintain therapeutic efficacy in clinical trials, requiring efficient methods for generating CAR-NK cells at scale. Here we develop a three-step strategy to generate high yields of induced NK (iNK) and CAR-iNK cells from human umbilical cord blood CD34+ haematopoietic stem and progenitor cells (CD34+ HSPCs). Starting from a single umbilical cord blood unit of CD34+ HSPCs, our method produces 14–83 million mature iNK cells or 7–32 million CAR-iNK cells with high expression levels of CD16 and CAR and undetectable T-cell contamination. Both fresh and thawed iNK and CAR-iNK cells demonstrate anti-tumour activities against various human cancer cells and prolong the survival of human tumour-bearing animals. The high yields of CAR-NK cells and reduced costs of our method’s CAR engineering support the broad applications of these cells for treating cancer patients.


  • Open Access

    Pluripotent stem cell-derived siTNK cells attack tumors via a synthetic CD8-CD28-TCR complex

    by Xiujuan Zheng, Fan Zhang, Yunqing Lin, Fangxiao Hu, Qitong Weng, Pengcheng Liu, Zhiqian Wang, Chenyuan Zhang, Yanhong Liu, Lijuan Liu, et al.

    SUMMARY: Tumor-associated antigen-specific T cell receptor (TCR)-engineered T cells offer a promising strategy for cancer therapy. Natural killer (NK) cells exhibit broad anti-tumor activity with low side effects but lack the capacity to recognize intracellular antigens. Here, we found that the human pluripotent stem cell (hPSC)-derived iNK cells, unlike tissue-isolated NK cells, expressed all four CD3 subunits at the transcriptome level. We introduced a synthetic gene-expressing complex (SCOTR), encoding a tumor antigen- specific TCR, CD8 coreceptor, and CD28 costimulatory molecule, into hPSCs to generate SCOTR-hPSCs. The SCOTR-hPSCs gave rise to abundant synthetic TCR complex-expressing iNK (siTNK) cells via an organoid induction method. These siTNK cells showed HLA-dependent, antigen-specific cytotoxicity against tumor cells and significantly suppressed tumor growth in tumor xenograft animal models, while also preserving universal non-specific tumor-killing activity. Collectively, siTNK cells, as hPSC-derived hybrid cells with dual features of adaptive T and inherent NK cells, offer an artificial cell source for human immunotherapies.